Shares of Monsanto advanced 5 percent after German firm Bayer offered to buy the company for $62 billion in cash.
U.S. stocks closed lower Monday in low volume trade as investors awaited further indications on the timing of the Federal Reserve's next rate hike.
CNBC's David Faber reports the latest on Bayer's $62 billion offer for Monsanto.
The FMHR traders take their positions on four stocks making news today, including Bayer's bid for Monsanto and Freeport-McMoran cancelling its oil and gas business IPO.
European stocks finished mostly lower on Monday as investors digested a fall in oil prices, mixed data out of the euro zone and the prospect of a U.S. rate hike in June.
CNBC's Simon Hobbs reports on all the market moving events in Europe today, including Unicredit, Fiat Chrysler and Bayer.
New York-based boutique bank Ducera Partners will score a monster payday if $62B the Bayer-Monsanto deal goes through.
U.S. stock index futures pointed to a mixed open on Monday, as oil prices dipped and traders mulled more hints of near-term monetary policy tightening.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
Some of the names on the move ahead of the open.
Stock index futures are pointing to a flat to lower open following Friday's advances, which allowed the S&P 500 to break a 3-week losing streak.
Bayer says it has offered $122 per share for Monsanto in an all-cash deal that values the U.S. company at $62 billion.
Werner Baumann, Bayer CEO, weighs in on the tax ramification of the combined companies.
Werner Baumann, Bayer CEO, explain why he went public with the $62 billion bid for Monsanto.
CNBC's Nancy Hulgrave reports on Bayer's big move to create a global leader in agriculture.
How tough will it be for Bayer, to convince investors that the Monsanto bid is worth it? Dealreporter assistant editor, Alex Tarrant weighs in.
Julien Jarmoszko, senior research manager at S&P Global Market Intelligence, talks about Bayer's decision to acquire Monsanto.
Werner Baumann, Bayer CEO, explains why he thinks the company's offer for Monsanto would likely pass regulatory scrutiny and doesn't see risk in the deal.
The pharmaceutical company Bayer has announced plans to acquire American biotech company Monsanto, making an all cash offer of $122 per share.
Jim Cramer says the strength of stocks are being masked by both the Fed and oil.